Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Here’s the latest company planning for gene-edited babies The news: A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

Agreement with IRRI marks Pairwise's third CGIAR partnership, enabling the research institute to use Fulcrum® genome editing technology to develop higher-yielding, more nutritious rice varieties that ...

Genetic testing is transforming healthcare through personalized medicine, enabling early diagnosis, targeted treatments, and a future of more precise, patient-centered care.

Discover ARK Invest's latest portfolio shifts into healthcare, crypto, and finance stocks. See key buys and sells by Cathie Wood.

KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...

Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third ...

Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using ...